Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Kara Long Roche

Showing results (1-10 of 116) with videos related to

Pageof 12
Sort By:
Journal of Minimally Invasive Gynecology|October 10, 2020
Salpingectomy for the Risk Reduction of Ovarian Cancer: Is It Time for a Salpingectomy-alone Approach?Thomas Boerner, Kara Long Roche
Gynecologic Oncology|September 2, 2019
State of the science: Evolving role of surgery for the treatment of ovarian cancerKara Long Roche, Ginger J Gardner
Gynecologic Oncology|June 13, 2020
Practical guidelines for triage to neoadjuvant chemotherapy in advanced ovarian cancer: Big risk, big reward…or too much risk?Kara Long Roche, Dennis S Chi
The New England Journal of Medicine|March 9, 2022
Decarbonizing the U.S. Health SectorJennifer Mueller, Kara Long Roche, Don Lieber
JAMA|June 1, 2023
Salpingectomy in Ovarian Cancer PreventionRebecca Stone, Joseph V Sakran, Kara Long Roche
Obstetrics and Gynecology|January 7, 2015
Surgical cytoreduction for disseminated benign disease after open power uterine morcellationAmanda Ramos, Amanda N Fader, Kara Long Roche
Clinical Advances in Hematology & Oncology : H&O|January 6, 2021
Update on the role of surgery in the management of advanced epithelial ovarian cancerAlli Straubhar, Dennis S Chi, Kara Long Roche
Gynecologic Oncology Reports|March 20, 2023
Prevention over screening for ovarian cancer in patients with high-risk germline mutations: Misinterpreting the findings of ALDOBeryl L Manning-Geist, Matthew Flint, Kara Long Roche
Urology|April 22, 2019
A Thoughtful Pause for Sparing OophorectomySamuel C Haywood, Kara Long Roche, Bernard H Bochner
Journal of the National Comprehensive Cancer Network : JNCCN|June 17, 2022
Costs and Barriers of Cancer Screening After Positive Genetic Testing: Are Actionable Mutations Becoming "Unactionable"?Ryan M Kahn, Sushmita Gordhandas, Emeline Aviki, et al.
Pageof 12

Showing results (1-10 of 116) with videos related to

Sort By:
Pageof 12
Journal of Minimally Invasive Gynecology|October 10, 2020
Salpingectomy for the Risk Reduction of Ovarian Cancer: Is It Time for a Salpingectomy-alone Approach?Thomas Boerner, Kara Long Roche
Gynecologic Oncology|September 2, 2019
State of the science: Evolving role of surgery for the treatment of ovarian cancerKara Long Roche, Ginger J Gardner
Gynecologic Oncology|June 13, 2020
Practical guidelines for triage to neoadjuvant chemotherapy in advanced ovarian cancer: Big risk, big reward…or too much risk?Kara Long Roche, Dennis S Chi
The New England Journal of Medicine|March 9, 2022
Decarbonizing the U.S. Health SectorJennifer Mueller, Kara Long Roche, Don Lieber
JAMA|June 1, 2023
Salpingectomy in Ovarian Cancer PreventionRebecca Stone, Joseph V Sakran, Kara Long Roche
Obstetrics and Gynecology|January 7, 2015
Surgical cytoreduction for disseminated benign disease after open power uterine morcellationAmanda Ramos, Amanda N Fader, Kara Long Roche
Clinical Advances in Hematology & Oncology : H&O|January 6, 2021
Update on the role of surgery in the management of advanced epithelial ovarian cancerAlli Straubhar, Dennis S Chi, Kara Long Roche
Gynecologic Oncology Reports|March 20, 2023
Prevention over screening for ovarian cancer in patients with high-risk germline mutations: Misinterpreting the findings of ALDOBeryl L Manning-Geist, Matthew Flint, Kara Long Roche
Urology|April 22, 2019
A Thoughtful Pause for Sparing OophorectomySamuel C Haywood, Kara Long Roche, Bernard H Bochner
Journal of the National Comprehensive Cancer Network : JNCCN|June 17, 2022
Costs and Barriers of Cancer Screening After Positive Genetic Testing: Are Actionable Mutations Becoming "Unactionable"?Ryan M Kahn, Sushmita Gordhandas, Emeline Aviki, et al.
Pageof 12